| ID | 55860 |
| JaLCDOI | |
| フルテキストURL | |
| 著者 |
Morizane, Shin
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sugimoto, Saeko
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Motoki, Takayuki
Department of Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Katayama, Norihisa
Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Omori, Masako
Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Iwatsuki, Keiji
Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
|
| 抄録 | Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques. The treatment for psoriasis has dramatically changed over the last 10 years with the introduction of biologics. However, the risk of cancer induced by biologics for psoriasis has not been fully analyzed, since these agents have such a short history of use. Here we report the case of a 74-year-old woman with psoriasis vulgaris and psoriatic arthritis complicated by breast cancer after systemic treatments including etretinate, cyclosporine, methotrexate, adalimumab, and ustekinumab.
|
| キーワード | psoriasis
systemic therapy
biologics
malignancy
|
| Amo Type | Case Report
|
| 出版物タイトル |
Acta Medica Okayama
|
| 発行日 | 2018-04
|
| 巻 | 72巻
|
| 号 | 2号
|
| 出版者 | Okayama University Medical School
|
| 開始ページ | 185
|
| 終了ページ | 187
|
| ISSN | 0386-300X
|
| NCID | AA00508441
|
| 資料タイプ |
学術雑誌論文
|
| 言語 |
英語
|
| 著作権者 | CopyrightⒸ 2018 by Okayama University Medical School
|
| 論文のバージョン | publisher
|
| 査読 |
有り
|
| PubMed ID |
